论文部分内容阅读
目的观察米非司酮治疗生育期和围绝经期子宫肌瘤临床效果。方法 30例生育期子宫肌瘤患者作为生育组,同期30例围绝经期子宫肌瘤患者作为绝经组。两组均采取米非司酮治疗,比较两组临床效果。结果两组患者治疗后肿瘤、子宫大小均小于治疗前,差异均有统计学意义(P<0.05)。两组患者治疗后雌二醇(E2)水平均有所降低,差异有统计学意义(P<0.05)。两组患者治疗后孕酮(P)水平均有所降低,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。生育组患者复发率为90.00%,高于绝经组的56.67%,差异有统计学意义(P<0.05)。结论米非司酮治疗围绝经期子宫肌瘤患者效果显著,但生育期患者复发率较高,需要特别注意。
Objective To observe the clinical efficacy of mifepristone in the treatment of uterine fibroids during the growth and peri-menopausal period. Methods Thirty cases of uterine fibroids in their reproductive age were selected as the fertility group and 30 cases of uterine fibroids in the perimenopausal period as the menopause group. Both groups were treated with mifepristone, the clinical effects of two groups were compared. Results The tumor size and uterine size of the two groups after treatment were all less than those before treatment (P <0.05). Estradiol (E2) levels in both groups decreased after treatment, with statistical significance (P <0.05). The levels of progesterone (P) decreased after treatment in both groups, with statistical significance (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). The recurrence rate in fertility group was 90.00%, which was higher than that in menopause group (56.67%), the difference was statistically significant (P <0.05). Conclusion The efficacy of mifepristone in the treatment of peri-menopausal uterine fibroids is remarkable, but the recurrence rate in patients with high growth period needs special attention.